echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma: Recombinant anti-CD38 all-human monoclonal antibody injections have been approved in clinical trials

    Fosun Pharma: Recombinant anti-CD38 all-human monoclonal antibody injections have been approved in clinical trials

    • Last Update: 2021-01-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 13, Fosun Pharma announced that its controlling subsidiary, Fuhong Hanxuan, had received approval from NMPA to approve its recombinant anti-CD38 all-human monoclonal antibody injection for clinical trials for the treatment of multiple myeloma.
    and Hanyu Pharmaceuticals intend to conduct Phase I clinical trials of the new drug in China (excluding Hong Kong, Macao and Taiwan) after the near-term conditions are met.
    the new drug is the Group (i.e., the Company and its controlling subsidiaries/units, the same between 2) independently developed Daretoyu monoclonal antibody biosynthesis drug, intended for the treatment of multiple myeloma.
    the date of this announcement , the D'Arreto U.S. single resistance in China was a mega-® for Janssen-Cilag International NV , which was approved for listing in July 2019 .
    Based on IQVIA CHPA data (provided by IQVIA, IQVIA is the world's leading provider of professional information and strategic consulting services for the pharmaceutical and health industry;
    as of December 2020, the Group's cumulative research and development investment in the new drug at this stage is approximately RMB16.24 million (unaudited).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.